(Reuters) - Cyclacel Pharmaceuticals Inc said an independent data and safety board determined that its lead drug was unlikely to show a statistically significant improvement in survival in some leukemia patients. The company's stock plunged about 47 percent to $1.49 before the bell on Tuesday. The board is evaluating the company's oral drug, sapacitabine, which is being tested in a late-stage study in patients with acute myeloid leukemia. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty) via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment